PCG
TXMD icon

Prosperity Consulting Group’s TherapeuticsMD TXMD Stock Holding History

Prosperity Consulting Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,500
Closed -$56.1K – 336
2024
Q1 		$56.1K Buy
+24,500
New +$56.7K 0.01% 328

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prosperity Consulting Group's TXMD Position: Q2 2024 in Review

Prosperity Consulting Group sold out of TherapeuticsMD (TXMD) in Q2 2024, closing a stake of 24,500 shares — an estimated $56.1K sold.

Prosperity Consulting Group first reported a position in TXMD in Q1 2024 and held it in 1 quarter. The position peaked at $56.1K in Q1 2024. 38 funds tracked by Wall St. Rank hold TXMD as of Q2 2024.

  • Prosperity Consulting Group reported no remaining TherapeuticsMD position as of Q2 2024 after selling out during the quarter.
  • Prosperity Consulting Group sold 24,500 TherapeuticsMD shares in Q2 2024, an estimated $56.1K.
  • Prosperity Consulting Group first reported a position in TherapeuticsMD in Q1 2024 and held it in 1 quarter.
  • Prosperity Consulting Group's TherapeuticsMD position peaked at $56.1K in Q1 2024.
  • 38 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2024.

Based on Prosperity Consulting Group's 13F filing for Q2 2024, filed 8 Aug 2024.